🏛️ Verified NIH Record • Updated 2026-03-18
A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis (NCT06598462)
A Phase 2, Randomized, Double-Blind, Multicenter, Placebo Controlled Study With an Extension to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis (ALAMERE)
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Uniquity One (UNI)
🩺 Plain-English Summary (8th-Grade Level)
Phase 2 study to evaluate the safety, tolerability, PK, immunogenicity, and pharmacodynamics of solrikitug in adult participants with eosinophilic esophagitis.
Who can join: Review the eligibility criteria below.
Location: Research Site 1039 — Dothan, Alabama
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (73 Sites)
Showing the first 25 of 73 sites.
- Research Site 1039 — Dothan, Alabama
- Research Site 1018 — Glendale, Arizona
- Research Site 1018 — Peoria, Arizona
- Research Site 1037 — Scottsdale, Arizona
- Research Site 1003 — Tucson, Arizona
- Research Site 1023 — Englewood, California
- Research Site 1005 — Irvine, California
- Research Site 1015 — San Diego, California
- Research Site 1034 — Aurora, Colorado
- Research Site 1027 — Cromwell, Connecticut
- Research Site 1040 — Inverness, Florida
- Research Site 1001 — Jacksonville, Florida
- Research Site 1049 — Miami, Florida
- Research Site 1007 — Boise, Idaho
- Research Site 1048 — Glenview, Illinois
- Research Site 1022 — Iowa City, Iowa
- Research Site 1033 — Topeka, Kansas
- Research Site 1032 — Chevy Chase, Maryland
- Research Site 1004 — Boston, Massachusetts
- Research Site 1024 — Ann Arbor, Michigan
- Research Site 1013 — Wyoming, Michigan
- Research Site 1006 — Plymouth, Minnesota
- Research Site 1042 — Creve Coeur, Missouri
- Research Site 1016 — Reno, Nevada
- Research Site 1045 — Freehold, New Jersey
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Eosinophilic Esophagitis (EoE)
- A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care — Phoenix, Arizona
- Surface EMG Testing on Swallowing in EoE Patients — Rochester, Minnesota
- A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis — Phoenix, Arizona
- Esophageal String Test Monitoring to Monitor Eosinophilic Esophagitis During Oral Immunotherapy — Philadelphia, Pennsylvania
- Effect of Dupilumab on the Muscle Function of the Esophagus (food Pipe) in Participants with Eosinophilic Esophagitis (EoE) — La Jolla, California
Explore by condition: All Eosinophilic Esophagitis (EoE) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.